Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study

Lei Zhang, Yan Wang, Xin Li, Ling Li, Xinhua Wang, Zhenchang Sun, Jingjing Wu, Xiaorui Fu, Xudong Zhang, Hui Yu, Guannan Wang, Yu Chang, Jiaqin Yan, Zhiyuan Zhou, Xiaolong Wu, Feifei Nan, Wencai Li, Mingzhi Zhang, Lei Zhang, Yan Wang, Xin Li, Ling Li, Xinhua Wang, Zhenchang Sun, Jingjing Wu, Xiaorui Fu, Xudong Zhang, Hui Yu, Guannan Wang, Yu Chang, Jiaqin Yan, Zhiyuan Zhou, Xiaolong Wu, Feifei Nan, Wencai Li, Mingzhi Zhang

Abstract

To compare the efficacy and safety of radiotherapy (RT) and chemotherapy of pegaspargase, gemcitabine, cisplatin and dexamethasone (DDGP) combined with RT in newly diagnosed stage I-II natural killer/T-cell lymphoma (NKTL), we designed a randomized, controlled, open-label, multicenter clinical trial. Data from 65 stage I-II NKTL patients whose diagnoses were confirmed using immunohistochemistry were enrolled from January 2011 to December 2013 in the First Affiliated Hospital of Zhengzhou University. Patients were randomly divided into the RT group (n = 35) and the DDGP combined with RT group (n = 30). There was a difference between the Eastern Cooperative Oncology Group (ECOG) score in the two arms (P = .013). The complete response rate (CRR) and objective response rate (ORR) of DDGP combined with RT group were superior to those in the RT group (CRR: 73.3% vs 48.6%; ORR: 83.3% vs 60.0%, respectively). The 5-year progression-free survival (PFS) rate and overall survival (OS) rate in the DDGP combined with RT group were higher than those in the RT group (82.9% vs 56.5% for PFS, P = .023; 85.7% vs 60.4% for OS, P = .040), and treatment methods and lactate dehydrogenase were independent risk factors. Myelosuppression (P < .001), gastrointestinal reactions (P < .001), abnormal liver function (P = .007), coagulation abnormalities (P < .001) and baldness (P < .001) were more likely to occur in the DDGP combined with RT group. In conclusion, DDGP combined with radiotherapy obviously obtained great efficacy and prolonged the survival time of patients, also the side effects were mild for stage I-II NKTL. This trial was registered at https://register.clinicaltrials.gov as #NCT01501136.

Keywords: DDGP; efficacy; natural killer/T-cell lymphoma; radiotherapy; safety.

© 2020 UICC.

References

REFERENCES

    1. Perry AM, Diebold J, Nathwani BN, et al. Non-hodgkin lymphoma in the developing world: review of 4539 cases from the international non-hodgkin lymphoma classification project. Haematologica. 2016;101:1244-1250.
    1. Lee H, Kim SH, Lee SW, Zheng Z, Bang D, Kim DY. A case of extranodal natural killer/T-cell lymphoma mimicking refractory Behcet's disease. Acta Derm Venereol. 2015;95:491-492.
    1. Asif S, Begemann M, Bennett J, Fatima R, Masood A, Raza S. Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: a case report. Mol Clin Oncol. 2019;10:397-400.
    1. Yang Y, Cao JZ, Lan SM, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/T-cell lymphoma. JAMA Oncol. 2017;3:83-91.
    1. Makita S, Tobinai K. Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematol Oncol Clin North Am. 2017;31:239-253.
    1. Jabbari AF, Delavarian Z, Hatami M, Rahimi H, Abdolvahed MR, Extranodal NK. T cell lymphoma with destruction of the uvulae: a case report. Iran J Otorhinolaryngol. 2017;29:101-108.
    1. Fox CP, Civallero M, Ko YH, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell project. Lancet Haematol. 2020;7:e284-284e294.
    1. Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10:85.
    1. Cheson BD, Pfistner B, Juweid ME, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
    1. Tang LC, Wang BY, Sun S, et al. Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. BMC Cancer. 2013;13:232.
    1. Suzuki R. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma. Semin Hematol. 2014;51:42-51.
    1. Bigley AB, Simpson RJ. NK cells and exercise: implications for cancer immunotherapy and survivorship. Discov Med. 2015;19:433-445.
    1. Dumauthioz N, Labiano S, Romero P. Tumor resident memory T cells: new players in immune surveillance and therapy. Front Immunol. 2018;9:2076.
    1. Liao Z, Zhou L, Wang C, et al. Characteristics of TCRζ, ZAP-70, and FcɛRIγ gene expression in patients with T- and NK/T-cell lymphoma. DNA Cell Biol. 2015;34:201-207.
    1. Cornfield DB, Papiez JS, Lynch JT, Rimsza LM. Natural killer-like T-cell lymphoma of the parotid in a patient infected with human immunodeficiency virus. Arch Pathol Lab Med. 2002;126:738-741.
    1. Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:401-404.
    1. Haverkos BM, Pan Z, Gru AA, et al. Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in north American and European cases. Curr Hematol Malig Rep. 2016;11:514-527.
    1. Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35:32-39.
    1. Liang JH, Wang L, Gale RP, et al. Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA. Blood Cancer J. 2017;7:e608.
    1. Zhang J, Yue L, Li YL. Clinical significance of peripheral blood EB virus detection in NK/T cell lymphoma patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25:460-464.
    1. Yao B, Li YX, Song YW, et al. Treatment option and outcomes for patients with primary non-Hodgkin lymphoma of the nasal cavity. Zhonghua Zhong Liu Za Zhi. 2006;28:58-61.
    1. Zang J, Li C, Luo SQ, et al. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy-a single institution experience. Ann Hematol. 2015;94:583-591.
    1. Wei W, Wu P, Li L, Zhang ZH. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematology. 2017;22:320-329.
    1. Jaccard A, Gachard N, Marin B, et al. GELA and GOELAMS Intergroup. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834-1839.
    1. Li L, Zhang C, Zhang L, et al. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma. Neoplasma. 2014;61:225-232.
    1. Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016;22:5223-5228.
    1. Zhang L, Li S, Jia S, et al. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. Oncotarget. 2016;7:58396-58404.
    1. Wu T, Liu QL, Hu YF, et al. Efficacy of extended-field intensity-modulated radiotherapy for early-stage NK/T cell lymphoma. Chinese. J Radiat Oncol. 2017;26:892-898.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner